Brief: Seagen Says EV-302 Study Met Its Dual Primary Endpoints
22/09/2023 11:30
Sept 22 (Reuters) - Astellas Pharma Inc 4503.T :
* PADCEV® (ENFORTUMAB VEDOTIN-EJFV) AND KEYTRUDA®
(PEMBROLIZUMAB)
SIGNIFICANTLY IMPROVE OVERALL SURVIVAL AND PROGRESSION-FREE
SURVIVAL IN PATIENTS WITH PREVIOUSLY UNTREATED ADVANCED BLADDER
CANCER IN PIVOTAL PHASE 3 EV-302 TRIAL
* SEAGEN INC: EV-302 STUDY MET ITS DUAL PRIMARY ENDPOINTS
Source text for Eikon: ID:nBw1dPk9ga
Further company coverage: 4503.T
((Reuters.Briefs@thomsonreuters.com;))